Literature DB >> 21661053

Assessment of involuntary choreatic movements in Huntington's disease--toward objective and quantitative measures.

Ralf Reilmann1, Stefan Bohlen, Florian Kirsten, E Bernd Ringelstein, Herwig W Lange.   

Abstract

Objective measures of motor impairment may improve the sensitivity and reliability of motor end points in clinical trials. In Huntington's disease, involuntary choreatic movements are one of the hallmarks of motor dysfunction. Chorea is commonly assessed by subitems of the Unified-Huntington's Disease Rating Scale. However, clinical rating scales are limited by inter- and intrarater variability, subjective error, and categorical design. We hypothesized that assessment of position and orientation changes interfering with a static upper extremity holding task may provide objective and quantitative measures of involuntary movements in patients with Huntington's disease. Subjects with symptomatic Huntington's disease (n = 19), premanifest gene carriers (n = 15; Unified-Huntington's Disease Rating Scale total motor score ≤ 3), and matched controls (n = 19) were asked to grasp and lift a device (250 and 500 g) equipped with an electromagnetic sensor. While subjects were instructed to hold the device as stable as possible, changes in position (x, y, z) and orientation (roll, pitch, yaw) were recorded. These were used to calculate a position index and an orientation index, both depicting the amount of choreatic movement interfering with task performance. Both indices were increased in patients with symptomatic Huntington's disease compared with controls and premanifest gene carriers for both weights, whereas only the position index with 500 g was increased in premanifest gene carriers compared with controls. Correlations were observed with the Disease Burden Score based on CAG-repeat length and age and with the Unified-Huntington's Disease Rating Scale. We conclude that quantitative assessment of chorea is feasible in Huntington's disease. The method is safe, noninvasive, and easily applicable and can be used repeatedly in outpatient settings. A use in clinical trials should be further explored in larger cohorts and follow-up studies.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 21661053     DOI: 10.1002/mds.23816

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  16 in total

Review 1.  Huntington disease: natural history, biomarkers and prospects for therapeutics.

Authors:  Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi
Journal:  Nat Rev Neurol       Date:  2014-03-11       Impact factor: 42.937

Review 2.  Novel methods and technologies for 21st-century clinical trials: a review.

Authors:  E Ray Dorsey; Charles Venuto; Vinayak Venkataraman; Denzil A Harris; Karl Kieburtz
Journal:  JAMA Neurol       Date:  2015-05       Impact factor: 18.302

3.  Quantitative motor assessment of dyskinesias in Parkinson's disease.

Authors:  Eva Schaeffer; Walter Maetzler; Inga Liepelt-Scarfone; Christian Sass; Ralf Reilmann; Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2015-02-25       Impact factor: 3.575

4.  Clinical and genetic investigation of a Brazilian family with Huntington's disease.

Authors:  L A Agostinho; M Spitz; J S Pereira; C L A Paiva
Journal:  Funct Neurol       Date:  2016 Jul-Sep

5.  Optical coherence tomography findings in Huntington's disease: a potential biomarker of disease progression.

Authors:  Hannah M Kersten; Helen V Danesh-Meyer; Dean H Kilfoyle; Richard H Roxburgh
Journal:  J Neurol       Date:  2015-08-02       Impact factor: 4.849

6.  Handwriting Movement Abnormalities in Symptomatic and Premanifest Huntington's Disease.

Authors:  Michael Caligiuri; Chase Snell; Sungmee Park; Jody Corey-Bloom
Journal:  Mov Disord Clin Pract       Date:  2019-08-16

7.  State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.

Authors:  Jessie S Gibson; Daniel O Claassen
Journal:  Expert Opin Pharmacother       Date:  2021-02-08       Impact factor: 4.103

8.  Automated Assessment of Movement Impairment in Huntington's Disease.

Authors:  M Bennasar; Y A Hicks; S P Clinch; P Jones; C Holt; A Rosser; M Busse
Journal:  IEEE Trans Neural Syst Rehabil Eng       Date:  2018-10       Impact factor: 3.802

9.  8OHdG is not a biomarker for Huntington disease state or progression.

Authors:  Beth Borowsky; John Warner; Blair R Leavitt; Sarah J Tabrizi; Raymund A C Roos; Alexandra Durr; Chris Becker; Cristina Sampaio; Allan J Tobin; Howard Schulman
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

10.  Quantitative motor assessment of muscular weakness in myasthenia gravis: a pilot study.

Authors:  Sarah Hoffmann; Jana Siedler; Alexander U Brandt; Sophie K Piper; Siegfried Kohler; Christian Sass; Friedemann Paul; Ralf Reilmann; Andreas Meisel
Journal:  BMC Neurol       Date:  2015-12-23       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.